SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Apogee Therapeutics, Inc. (APGE) has a negative trailing P/E of -20.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -4.99%.
Criteria proven by this page:
- VALUE (75/100, Pass) — analyst target implies upside (+19.4%).
- Trailing Earnings Yield -4.99% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
- Analyst consensus target $105.63 (+19.4% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 52/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
75/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
100/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — APGE
Valuation Multiples
P/E (TTM)-20.0
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio5.67
P/S Ratio0.00
EV/EBITDA-16.6
Per Share Data
EPS (TTM)$-4.22
Book Value / Share$14.89
Revenue / Share$0.00
FCF / Share$-3.83
Yields & Fair Value
Earnings Yield-4.99%
Dividend Yield0.00%
Analyst Target$105.63 (+19.4%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2022 |
-27.0 |
0.00 |
7.57 |
0.00 |
- |
| 2023 |
-16.9 |
-0.15 |
3.73 |
0.00 |
- |
| 2024 |
-13.7 |
-0.14 |
3.49 |
0.00 |
- |
| 2025 |
-17.9 |
-0.64 |
5.07 |
0.00 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2022 |
$-0.79 |
$0.00 |
$-39.79M |
- |
| 2023 |
$-1.66 |
$0.00 |
$-83.99M |
- |
| 2024 |
$0.00 |
$0.00 |
$0.00 |
- |
| 2025 |
$-4.22 |
$0.00 |
$-255.84M |
- |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$-4.63 |
$-5.74 – $-3.83 |
$0.00 |
$0.00 – $0.00 |
11 |
| 2027 |
$-5.57 |
$-7.10 – $-4.76 |
$4.17M |
$4.17M – $4.17M |
11 |
| 2028 |
$-6.63 |
$-12.18 – $-4.95 |
$6.25M |
$6.25M – $6.25M |
10 |
| 2029 |
$-6.09 |
$-6.09 – $-6.09 |
$196.21M |
$196.21M – $196.21M |
4 |
| 2030 |
$-0.92 |
$-0.92 – $-0.92 |
$817.53M |
$817.53M – $817.53M |
4 |
